Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Warning Letters

Warning Letters

                        About Warning and Close-Out Letters Home
          Inspections, Compliance, Enforcement, and Criminal Investigations
          Compliance Actions and Activities
          Warning Letters
          Mei Lan Thailand Co., Ltd. - 672783 - 01/22/2024Warning Letters WARNING LETTER
      Mei Lan Thailand Co., Ltd.
            
      MARCS-CMS 672783 —           January 22, 2024


    
Share
    Post
    Linkedin

    Email
    PrintDelivery Method: 
        VIA UPS
      
      
              Product: 
        Drugs            


Recipient:

                      Recipient Name
              Mrs. Lan Pu
                                Recipient Title
              Managing Director
          
            Mei Lan Thailand Co., Ltd.

          
                      35/252-253 Moo 2, Tambol Bangnamched, Muang DistrictMuang Samut Sakhon,Samut Sakhon 74000Thailand            

       Issuing Office:
        
         
          Center for Drug Evaluation and Research | CDER
        
         
          United StatesSecondary Issuing Offices
          United States

 

 

**Warning Letter** 320-24-16

January 22, 2024
Dear Mrs. Lan Pu:

The U.S. Food and Drug Administration (FDA) notified your site, Mei Lan (Thailand) Co., Ltd., FEI 3012190301, at 35/252-253 Moo 2 , Tambol Bangnamched, Muang District, Muang Samut Sakhon, Samutsakorn, Thailand, of a planned inspection of your drug manufacturing facility from September 18 to 22, 2023.

Your firm is registered as an active pharmaceutical ingredient (API) manufacturer and manufactures crude **(b)(4)**.

On May 23, 2023, the FDA sent an electronic notice of inspection to the contact email address provided in your registration file. This request went unanswered, as did the second and third email requests sent on June 6 and 21, 2023, respectively. An FDA representative then attempted to contact your U.S. Agent on August 25, 2023. A fourth email attempt to contact you was sent on August 29, 2023, but you failed to respond. The Agency then sent a follow-up written request via UPS, that was delivered to the physical address provided in your registration file on August 29, 2023. Delivery to you was confirmed by the shipper, but you failed to respond.

Under section 501(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(j), your drugs are adulterated in that they have been manufactured, processed, packed, or held in an establishment that delays, denies, or limits an inspection, or refuses to permit entry or inspection.

See FDA’s guidance document, *Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection*, at https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm360484.pdf.

FDA placed your firm on Import Alert 55-03 on January 18, 2024.

Until FDA is permitted to inspect your facility and confirms compliance with CGMP, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at Mei Lan (Thailand) Co., Ltd., at 35/252-253 Moo 2, Tambol Bangnamched, Muang District, Muang Samut Sakhon, Samutsakorn, Thailand into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).

After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and/or submit a request to schedule an FDA inspection.

Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012190301 and ATTN: Rokhsana Jazi.

Sincerely,
/S/

Francis Godwin
Director
Office of Manufacturing Quality
Office of Compliance
Center for Drug Evaluation and Research

                                                                                  Content current as of:
      01/30/2024
               
                
Regulated Product(s)
		 DrugsMore Warning Letters

     
    Warning Letters

          
                        About Warning and Close-Out Letters
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop